This post hoc analysis of the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study investigates the effect of focused atorvastatin therapy
Some of the pitfalls of treating CHD patients in the “real world” should also be considered
August 1, 2022 – The atorvastatin experimental proof of concept trial to treat cavernous malformations with symptomatic hemorrhage, hosted at the University of Chicago, has
National Institutes of Health
Compare prices and print coupons for Atorvastatin (Generic Lipitor) and other drugs at CVS, Walgreens, and other pharmacies
Flu, Hepatitis, Pneumonia, Shingles, Hepatitis B and many more available everyday
A041702 is a randomized phase 3 study led by the Alliance for Clinical Trials in Oncology that is currently enrolling through the NCI National Clinical Trials Network (NCTN)
A post hoc analysis was conducted based on a Cochrane review on statins for the primary prevention of cardiovascular diseases
5 Atorvastatin-group patients were titrated to LDL-C goals of <80 mg/dl (2
Atorvastatin oral tablet dosage and frequency will depend upon several factors, the most important being the medical condition it is being targeted for and The VYVA (VYtorin Versus Atorvastatin) trial reported that the proportion of patients achieving NCEP-defined LDL-C goals with different ezetimibe/simvastatin combinations (10mg/10mg, 10mg/20mg, 10mg/40mg or 10mg/80mg) were higher than with corresponding atorvastatin dosages, but the percentages of patients achieving the
5 months
Atorvastatin calcium tablets significantly reduced the rate of major cardiovascular events (primary endpoint events) (83 events in the atorvastatin calcium tablets group vs
Background: More than a million Americans harbor a cerebral cavernous angioma (CA), and those who suffer a prior symptomatic hemorrhage have an exceptionally high rebleeding risk
ALLIANCE (Aggressive Lipid‐Lowering Initiation Abates New Cardiac Events) ASCOT indicates Anglo‐Scandinavian Cardiac Outcomes Trial; ASPEN, Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non‐Insulin‐Dependent Diabetes Mellitus; CARDS, Collaborative Atorvastatin Diabetes Study; CHD, coronary
However, there is no long-term survival study that evaluated this statin
5 to 80 mg daily
There were 101 well-controlled, well-documented Pfizer-sponsored atorvastatin clinical trials that began in or after 1992 and were completed by 30 March 2012
TNT was the first trial which showed that aggressive lipid lowering therapy was more protective The reason for this is twofold: first, trials of atorvastatin have not, in general, been large enough to use heart disease (heart attack and stroke) or death as their primary outcome For example, the results of ALLIANCE 194 show a reduction in LDL cholesterol at follow-up of 0